1016 related articles for article (PubMed ID: 28274484)
1. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
2. Impact of preformed T-cell alloreactivity by means of donor-specific and panel of reactive T cells (PRT) ELISPOT in kidney transplantation.
Gandolfini I; Crespo E; Baweja M; Jarque M; Donadei C; Luque S; Montero N; Allesina A; Perin L; Maggiore U; Cravedi P; Bestard O
PLoS One; 2018; 13(7):e0200696. PubMed ID: 30059561
[TBL] [Abstract][Full Text] [Related]
3. Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.
Shiu KY; McLaughlin L; Rebollo-Mesa I; Zhao J; Burton H; Douthwaite H; Wilkinson H; Semik V; Dodd PC; Brookes P; Lechler RI; Hernandez-Fuentes MP; Kemper C; Dorling A
Kidney Int; 2017 Feb; 91(2):477-492. PubMed ID: 27988211
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Functional Noninvasive Immune Monitoring in the ESCAPE Study for Prediction of Subclinical Renal Allograft Rejection.
Crespo E; Roedder S; Sigdel T; Hsieh SC; Luque S; Cruzado JM; Tran TQ; Grinyó JM; Sarwal MM; Bestard O
Transplantation; 2017 Jun; 101(6):1400-1409. PubMed ID: 27362314
[TBL] [Abstract][Full Text] [Related]
5. Monitoring alloimmune response in kidney transplantation.
Bestard O; Cravedi P
J Nephrol; 2017 Apr; 30(2):187-200. PubMed ID: 27245689
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation.
Bestard O; Cruzado JM; Lucia M; Crespo E; Casis L; Sawitzki B; Vogt K; Cantarell C; Torras J; Melilli E; Mast R; Martinez-Castelao A; Gomà M; Reinke P; Volk HD; Grinyó JM
Kidney Int; 2013 Dec; 84(6):1226-36. PubMed ID: 23783240
[TBL] [Abstract][Full Text] [Related]
7. Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies.
García-Carro C; Dörje C; Åsberg A; Midtvedt K; Scott H; Reinholt FP; Holdaas H; Seron D; Reisæter AV
Transplantation; 2017 Jun; 101(6):1410-1415. PubMed ID: 27163535
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes: Results From Clinical Trials in Organ Transplantation-17.
Faddoul G; Nadkarni GN; Bridges ND; Goebel J; Hricik DE; Formica R; Menon MC; Morrison Y; Murphy B; Newell K; Nickerson P; Poggio ED; Rush D; Heeger PS;
Transplantation; 2018 Apr; 102(4):673-680. PubMed ID: 29189482
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
[TBL] [Abstract][Full Text] [Related]
10. Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection.
Mendoza Rojas A; van Gelder T; de Kuiper R; Reijerkerk D; Clahsen-van Groningen MC; Hesselink DA; Baan CC; van Besouw NM
Sci Rep; 2021 Jun; 11(1):12445. PubMed ID: 34127739
[TBL] [Abstract][Full Text] [Related]
11. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
[TBL] [Abstract][Full Text] [Related]
12. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
Loupy A; Vernerey D; Tinel C; Aubert O; Duong van Huyen JP; Rabant M; Verine J; Nochy D; Empana JP; Martinez F; Glotz D; Jouven X; Legendre C; Lefaucheur C
J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant donor-specific Interferon-gamma-producing cells and acute rejection of the kidney allograft.
Slavcev A; Rybakova K; Svobodova E; Slatinska J; Honsova E; Skibova J; Viklicky O; Striz I
Transpl Immunol; 2015 Oct; 33(2):63-8. PubMed ID: 26254561
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients.
Kim SH; Oh EJ; Kim MJ; Park YJ; Han K; Yang HJ; Kim JY; Choi BS; Yang CW; Kim YS; Bang BK
Transplant Proc; 2007 Dec; 39(10):3057-60. PubMed ID: 18089321
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of B cells in acute kidney transplant rejection.
Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
[TBL] [Abstract][Full Text] [Related]
16. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
17. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
[TBL] [Abstract][Full Text] [Related]
18. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving T-cell depleting induction therapy.
Crespo E; Lucia M; Cruzado JM; Luque S; Melilli E; Manonelles A; Lloberas N; Torras J; Grinyó JM; Bestard O
PLoS One; 2015; 10(2):e0117618. PubMed ID: 25689405
[TBL] [Abstract][Full Text] [Related]
20. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation.
Lúcia M; Luque S; Crespo E; Melilli E; Cruzado JM; Martorell J; Jarque M; Gil-Vernet S; Manonelles A; Grinyó JM; Bestard O
Kidney Int; 2015 Oct; 88(4):874-87. PubMed ID: 26176829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
